<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.biopharmawatch.com/news/CYTK/cytokinetics-myqorzo-prescribing-information-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T09:00:00.000Z</news:publication_date>
      <news:title>Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ACRS/aclaris-phase-2b-trial-modzatinib-lichen-planus</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T08:30:00.000Z</news:publication_date>
      <news:title>Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ACRS/aclaris-phase-2-results-bosakitug-atopic-dermatitis</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T08:28:00.000Z</news:publication_date>
      <news:title>Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-11-16</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T07:15:54.444Z</news:publication_date>
      <news:title>Troculeucel Phase 1: Biotech Catalysts Nov 16, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T07:00:00.000Z</news:publication_date>
      <news:title>Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/OCS/oculis-fda-ind-clearance-privosegtor-ms-relapses</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T07:00:00.000Z</news:publication_date>
      <news:title>Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EVO/evotec-secures-grant-drug-safety-testing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T06:57:00.000Z</news:publication_date>
      <news:title>Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LKFT/lakefront-new-share-repurchase-program</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T06:30:00.000Z</news:publication_date>
      <news:title>Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HCM/hutchmed-expanded-coverage-nrdl-elunate-orpathys</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T04:00:00.000Z</news:publication_date>
      <news:title>HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-lisaftoclax-olverembatinib-nrdl-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T23:30:00.000Z</news:publication_date>
      <news:title>Ascentage Pharma Announces Inclusion of Lisaftoclax in China&apos;s 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MESO/mesoblast-asx-investor-day-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T23:16:00.000Z</news:publication_date>
      <news:title>Mesoblast Showcased at ASX Premier Investor Day Event</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-nominates-ide101-candidate</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T20:00:00.000Z</news:publication_date>
      <news:title>IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DRTS/alpha-dart-recurrent-glioblastoma-trial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T18:00:00.000Z</news:publication_date>
      <news:title>New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events – Conference Call Scheduled for 8:30am ET November 16</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-vk2735-obesity-week-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T17:05:00.000Z</news:publication_date>
      <news:title>Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HELP/helus-pharma-phase-3-approach-study-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T17:00:00.000Z</news:publication_date>
      <news:title>Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CVS/cvs-health-glp-1-benefits-affordability-challenge</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T15:00:00.000Z</news:publication_date>
      <news:title>CVS Health study highlights GLP-1 benefits and the affordability challenge</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-q3-2026-results-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T12:00:00.000Z</news:publication_date>
      <news:title>Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-ivonescimab-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T12:00:00.000Z</news:publication_date>
      <news:title>Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-business-update-q3-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T12:00:00.000Z</news:publication_date>
      <news:title>Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LLY/lilly-obesityweek-2026-data-presentation</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-14T17:01:00.000Z</news:publication_date>
      <news:title>Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AMLX/amylyx-avexitide-phase-3-results-obesityweek-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-14T17:00:00.000Z</news:publication_date>
      <news:title>Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/WWB/windward-bio-nasdaq-ipo</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-14T15:57:00.000Z</news:publication_date>
      <news:title>Innovative Immunology Biotech Windward Bio Lists on Nasdaq</news:title>
    </news:news>
  </url>
</urlset>